HOME >> BIOLOGY >> NEWS
Gene silencing directs muscle-derived stem cells to become bone-forming cells

BALTIMORE - Using a relatively new technology called RNA interference to turn off genes that regulate cell differentiation, University of Pittsburgh researchers have demonstrated they can increase the propensity of muscle-derived stem cells (MDSCs) to become bone-forming cells. Based on these results, the investigators believe that by turning off specific genetic factors they can control the capacity of MDSCs as a means of treating various musculoskeletal diseases and injuries.

RNA interference is a simple yet powerful technique that uses short interfering RNAs (siRNAs) small molecules that prevent a gene from being expressed to turn off the production of specific proteins in a cell. In their study, the Pitt researchers generated siRNAs to two mouse genes: MyoD1, a master gene that regulates the formation of muscle cells or fibers (myogenesis), and Smad6, which encodes a molecule that specifically inhibits a cell's ability to respond to bone-forming, or osteogenic, signals.

When the researchers examined cultured cells in which myogenesis was inhibited, they found a significant increase in the cells' bone-forming potential. However, contrary to their expectations, the researchers did not observe any bone formation when the cells were implanted in skeletal muscle. Yet, when they turned off ostegenic inhibition in these same cells using Smad6 siRNA prior to implanting them in mice, 60 percent of the mice developed radiologically detectable bone within three weeks.

"By understanding the genetic mechanisms that regulate a cell's propensity to differentiate into one type of cell line over another, we may be able to regulate their ability to generate bone for the treatment of various diseases and injuries of the musculoskeletal system, such as osteoporosis or severe fractures," said first author Jonathan B. Pollett, Ph.D., research associate, department of orthopaedic surgery, Children's Hospital of Pittsburgh. Corresponding author Johnny Huard,
'"/>


1-Jun-2006


Page: 1 2

Related biology news :

1. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
2. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
3. Pathway toward gene silencing described in plants
4. miRNA-mediated silencing of mRNAs
5. New mechanism for essential genome-wide gene silencing identified
6. Proteins role in hemoglobin gene silencing identified
7. Prediction of a prokaryotic RNA-silencing system
8. Twin molecular scissors link creation of microRNAs with gene-silencing
9. Gene silencing technique offers new strategy for treating, curing disease
10. Molecular steps involved in the creation of gene-silencing microRNAs identified
11. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: